{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:54:39Z","timestamp":1795089279644,"version":"4.10.2"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.eururo.2021.07.026","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T18:30:22Z","timestamp":1628879422000},"page":"693-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study"],"prefix":"10.1016","volume":"80","author":[{"given":"Patrick","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamim","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Patenaude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Yick Chin","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arbind","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Czaykowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K.S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupi","family":"Mangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Keshavarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-5357","authenticated-orcid":false,"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.07.026_bib0005","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0010","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.07.026_bib0020","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrurol.2017.87","article-title":"Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach","volume":"14","author":"Siva","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.07.026_bib0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.07.026_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","article-title":"Checkpoint inhibitor immunotherapy in kidney cancer","volume":"17","author":"Xu","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0050","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ejca.2013.02.032","article-title":"Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort","volume":"49","author":"Iacovelli","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0055","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2014.25","article-title":"First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC","volume":"110","author":"Ko","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0060","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.07.026_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2018.02.009","article-title":"Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study","volume":"94","author":"Molina","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0070","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2021.07.026_bib0075","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0080","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2021.07.026_bib0085","doi-asserted-by":"crossref","first-page":"100708","DOI":"10.18632\/oncotarget.20022","article-title":"Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis","volume":"8","author":"Santini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2021.07.026_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2018.07.018","article-title":"Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma","volume":"16","author":"Barata","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0095","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.21873\/anticanres.14730","article-title":"Stereotactic radiotherapy for the treatment of patients with oligo-progressive metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitor: data from the real world","volume":"40","author":"Gebbia","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2021.07.026_bib0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the GETUG group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0105","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clon.2017.04.035","article-title":"The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis","volume":"29","author":"Chan","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0110","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1002\/cncr.33109","article-title":"Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy","volume":"126","author":"Friedes","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0115","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2021.07.026_bib0120","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1111\/cas.14605","article-title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer","volume":"111","author":"Kagawa","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eururo.2021.07.026_bib0125","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1186\/s12885-019-6449-8","article-title":"Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer","volume":"19","author":"Kissel","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","article-title":"Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the \u2018TOaSTT\u2019 database","volume":"16","author":"Kroeze","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1159\/000448804","article-title":"Maximizing benefits from maintenance pemetrexed with stereotactic ablative radiotherapy in oligoprogressive non-squamous non-small cell lung cancer","volume":"9","author":"Lu","year":"2016","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: delaying the need to start or change systemic therapy?","volume":"124","author":"Merino","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0145","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00270-018-02153-x","article-title":"Local thermal ablation with continuous EGFR tyrosine kinase inhibitors for EGFR-mutant non-small cell lung cancers that developed extra-central nervous system (CNS) oligoprogressive disease","volume":"42","author":"Ni","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0150","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/j.cllc.2017.04.002","article-title":"Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation","volume":"18","author":"Qiu","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.eururo.2021.07.026_bib0155","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.21873\/invivo.11999","article-title":"High-dose radiotherapy for oligo-progressive NSCLC receiving EGFR tyrosine kinase inhibitors: real world data","volume":"34","author":"Santarpia","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.eururo.2021.07.026_bib0160","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eururo.2021.07.026_bib0165","article-title":"Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib","volume":"19","author":"Weiss","year":"2019","journal-title":"Cancer Treat Res Commun"},{"issue":"6 suppl","key":"10.1016\/j.eururo.2021.07.026_bib0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2021.39.6_suppl.313","article-title":"Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"39","author":"Tannir","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821019291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821019291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:09:41Z","timestamp":1759583381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821019291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0302283821019291"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.07.026","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}